Introduction: The follow-up of men with prostate cancer forms a large part of many urologists workload. However, a rising PSA usually announces disease progression long before any clinically apparent symptom. Thus, many men can be safely monitored with PSA measurement alone. To facilitate this process, PSA tracking software was introduced to remotely monitor PSA results, minimising the work required for follow-up.
IntroductIon
Over the past 20 years there has been worldwide increase in the incidence of prostate cancer 1 . This increase is due to improved awareness, increased prostate specific antigen (PSA) testing and increased availability of trans-rectal ultrasound guided biopsies (TRUS). Once treated, and the patients PSA remains stable or suppressed for two years, they are considered to have stable prostate cancer. Most stable prostate cancer patients are followed-up routinely in an outpatient department (OPD) for many years, often with little change in their disease status. Thus, the increasing numbers of stable prostate cancer patients is placing a burden on many urology departments' resources.
In response, PSA Tracking System (PTS) software has been developed to facilitate the remote surveillance of these stable prostate cancer patients, without the patient having to attend the hospital OPD. The system has been introduced as new model of patient care that would reduce the burden of longterm management, by facilitating follow-up by a specialist nurse, rather than by a consultant urologist. Stable prostate cancer patients are particularly suited to this form of follow up: because, once treated, a change in PSA will announce disease progression long before any clinical symptom or sign 2, 3, 4 .
PTS software and nurse led prostate cancer follow-up was introduced into our institution in 2006. The goal of this study was to assess the provision of services in relation to these patients and assess local service development. A secondary goal was to assess if this automated computerised system reduced the burden of long-term follow-up and if there are any benefits for the patients on the PTS.
Methods
In 
results

Patient demographics
At time of this study, there were 65 patients enrolled in the PTS. Data was obtained on all 65 patients. The median age of patients was 81 years, (IRQ 57-94). The median year of diagnosis of prostate cancer was 2007, (IRQ 1996 (IRQ -2011 . The majority of patients were entered onto the PTS tracker after 2010, (Table 1) . The median duration for a patient on the PTS was 12 months, (IRQ 9-30).
Clinical stage, grade and treatment
The median PSA at diagnosis was 17, (IRQ 3.1-2012) ( Table  2 ). The local clinical stage as determined by digital rectal examination (DRE) varied. 34 (53%) patients had organconfined disease; 3 patients gad pT1a, 14 patients were pT1c, 17 patients were pT2a and 1 patient was pT2b. 30 (47%) patients had locally advanced disease; 22 had pT3 disease and 8 had pT4 disease (Table 2) .
Gleason grade varied less between patients. 33 (50.7%) patients had Gleason 6 disease, 10 (15.3%) had Gleason 7 (3+4), 4 (6.1%) had Gleason 7 (4+3), 2 (3%) had Gleason 4+5 and 1(1.5%) patient was Gleason 5+4. TRUS guided biopsies were not performed in 14 patients as PSA and DRE alone were used to diagnose the prostate cancer, ( Table 2 ).
8 (12.3%) of patients had radical treatment (7 patients had radiotherapy, 1 patient had brachytherapy) for their prostate cancer, 21 (32.3%) of patients were on watchful waiting programme. 36 (55.4%) of patients on hormonal treatment for their prostate cancer, ( Table 2 ). The current median PSA of the patient cohort is 2.2, (IRQ 0.1-336).
Economic benefits
Since the introduction of the PTS, the tracking system saved 274 outpatients clinic appointments. For individual patients, a median of 3 appointments was saved, (IRQ 1-6). For the urology consultant, 4090 minutes of time was saved, amounting to 12 full outpatient clinics, (Table 3) . By removing the need for the patient to attend the hospital for review, each patient avoided having travel a median of 126 miles, (IRQ 54-444), and taking a median of 228 minutes, (IRQ 80-602). In total, 21700 patient miles and 30400 patient minutes were saved by not needing to travel for their hospital appointments (Table 3) .
dIscussIon
The aim of this paper was to highlight the emerging importance of healthcare software; and more specifically discuss the use of the PSA tracker in monitoring men with stable prostate cancer. We found the PTS reduced the clinical, administrative and personal burden required for the follow-up of these patients. In our hospital, we found that system saved 274 outpatient appointments. This represented a potential saving of £32,000 for our healthcare organisation. However, the real benefit was that the system increased the department's capacity to assess new patients; by removing the need to regularly review stable prostate cancer patients in the OPD. For individual patients, it meant that they did not have to travel to the hospital for review, saving them time and money.
Computerised systems are just one of the features illustrating 5 . Therefore it is the belief of many that the next step of such a tracking the system would be the expansion of such a system into other healthcare organisations. Indeed, it is now the goal of the transforming cancer follow-up initiative of Northern Ireland Cancer Network (NICaN) prostate cancer subgroup to develop a PTS for all stable prostate cancer patients in Northern Ireland.
The current PTS used in Altnagelvin Area Hospital is a standalone programme that is now seven years old. It will not be adopted by the NICaN prostate cancer subgroup for the surveillance of prostate cancer patients. Instead, it is likely that a new programme will be developed. A key feature of this future programme would be the incorporation of this system into an EPR. The amalgamation of computerised health care systems would allow a detailed overview of the patient to include their past medical history, diagnosis, treatment and subsequent management. A secondary benefit in this integration, would allow any patients past medical history be reviewed instantly, almost anywhere within the health care network 6, 7 .
One of the general concerns with any computerised health care system is that patients can be lost in the system or lost to follow-up. This was discussed by Singh et al, who studied the use of an integrated EPR in aiding with effective management of lung cancer. They found that the proportion of people 'slipping through the system': that is, not being followed up regarding their malignancy decreased with use of electronic systems compared to standard methods. Indicating that electronic follow up of certain patients was safe and efficient 8 . Similarly, our PTS generated reminders and correspondence automatically, in addition to flagging all patients that were due a PSA ensuring that it was very hard for a patient to be lost to follow up.
The initial starting cost of implementing a PTS has to be considered. Firstly, there is a considerable investment of time and money that is needed to develop such a system. Secondly, the task of transferring information from paper to EPR will be a considerable administrative process 9 . However, the improvement in efficiency, quality of care, public satisfaction and healthcare policy-making is likely to be significant.
conclusIon
The PSA tracker has clear advantages; it reduces the need to review stable patients in the OPD, this has associated cost savings for the health care organisation. This example, further demonstrates the benefits of implanting healthcare software for patients and hospitals.
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